

Press release  
Lund 25 April 2014

## **New date for Enzymaticas Interim Report January-March: May 19, 2014**

Enzymaticas report for the first quarter of 2014 will be announced on May 19 instead of May 20 as previously announced. The change is done with respect to the company's Annual General Meeting held in Lund on May 19.

### **For more information, please contact:**

Michael Edelborg Christensen, CEO, Enzymatica AB

Tel: +46 768 14 41 66 | E-mail: [michael.christensen@enzymatica.se](mailto:michael.christensen@enzymatica.se)

Johan Wennerholm, CFO, Enzymatica AB

Tel: +46 730 429 997 | E-mail: [johan.wennerholm@enzymatica.se](mailto:johan.wennerholm@enzymatica.se)

### **About Enzymatica AB (publ)**

Enzymatica AB (publ) is a publicly traded biotechnology company focusing on research, development and sales of medical device products based on a patented enzyme technology. Enzymatica has several projects in the pipeline for diseases of the skin, throat and mucous membranes. Enzymatica has two registered medical device products, PeriZyme® Chewing Gum CE, against oral cavity diseases and ColdZyme® Mouth Spray CE against the common cold, the latter recently launched throughout the country.

### **About Enzymatica online**

[Enzymatica's press room »](#)

[Enzymatica's website »](#)

[Enzymatica on LinkedIn »](#)

[Enzymatica on twitter »](#)

[For Investors »](#)

[For Investors »](#)

[ColdZyme website »](#)

[ColdZyme on facebook »](#)